Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Bortezomib extends lung cancer survival

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial.

9 Jun 2006

Thalomid gets FDA approval to treat multiple myeloma

Thalomid (thalidomide) has been given a new lease of life following the United States Food and Drug Administration (FDA) approval for the drug to be used in combination with the steroid dexamethasone for the treatment of newly diagnosed multiple myeloma.

29 May 2006

A review of percutaneous kyphoplasty

A procedure that fills in fractured vertebrae with injected cement has not been shown to improve a person's back pain or quality of life, according to a new analysis of studies.

16 May 2006

Four subtypes of blood cancer identified

Scientists at Dana-Farber Cancer Institute and collaborators have identified four distinct genetic subtypes of multiple myeloma, a deadly blood cancer, that have different prognoses and might be treated most effectively with drugs specifically targeted to those subtypes.

26 Apr 2006

Breast implants not associated with an increased risk of cancer

Implants were associated with a decrease in breast cancer risk and an increased lung cancer risk, but these results likely reflect the lifestyles and smoking habits of the women in the study rather than an effect of the implants themselves, the authors conclude.

18 Apr 2006

Thalidomide improves remission in myeloma

Myeloma is one of the least curable cancers and involves plasma cells, the white blood cells that produce antibodies.

9 Mar 2006

FDA grants priority review for Revlimid

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma.

6 Mar 2006

Loyola to study for first time IV medication for osteopenia and inflammatory bowel diseases

Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.

10 Jan 2006

Thalomid gives hope for blood cancer sufferers

Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.

9 Jan 2006

Compound from Salinispora (marine bacteria) kills blood cancer cells

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.

21 Nov 2005

New treatments suggest that cancer is on the run!

People suffering from cancer will be encouraged by a cluster of recent reports on successful new treatments for several different forms of cancer.

24 Oct 2005

Researchers learn to rapidly rebuild immunity in immune-suppressed cancer patients

Patients with multiple myeloma suffer from a malignant proliferation of plasma cells in their bone marrow. The standard treatment for this form of cancer is high-dose chemotherapy and transplantation of one's own blood-producing adult stem cells; however, this aggressive treatment wipes out the mature immune-system cells of patients – leaving them vulnerable to infection.

20 Oct 2005

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

In studies with mice, treatment with a new monoclonal antibody that targets immune system B cells has shown considerable promise for treating leukemias, autoimmune diseases and transplant rejection, according to immunologists at Duke University Medical Center.

11 Oct 2005

Scintigraphy scan may help clinicians properly diagnose and then treat two forms of cardiac amyloidosis

"Clinically, this finding helps differential diagnosis and reduces the risk of misdiagnosis between two conditions with very different therapeutic options," said Claudio Rapezzi, M.D. from the University of Bologna and S. Orsola-Malpighi Hospital in Bologna, Italy.

21 Sep 2005

Drug AMD-3100 may help cancer patients who need stem cell transplants

A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.

19 Sep 2005

Rev/Dex combo looks like a breakthrough treatment for multiple myeloma

Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (Revlimid) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.

1 Sep 2005

Relative of the celebrated COX-2 inhibitor celecoxib is tough tumor fighter

A close structural relative of the celebrated COX-2 inhibitor celecoxib (brand name: Celebrex) is a potent tumor fighter, able to wipe out tumor cells that are resistant to conventional chemotherapies, according to an interdisciplinary team of researchers from the University of Southern California.

29 Aug 2005

Loyola researchers hope that zoledronic acid will be effective and safe for patients with inflammatory bowel diseases (IBD)

26 Jul 2005

Breast cancer drug Herceptin soon to be widely available on NHS

The British health secretary Patricia Hewitt has ordered a fast-track assessment of Herceptin, a drug which has shown great promise in treating the early stages of breast cancer.

23 Jul 2005

$New protective drugs called bisphosphonates reduce pain and fractures in metastatic breast cancer$

New protective drugs called bisphosphonates reduce pain and fractures in metastatic breast cancer

When breast cancer spreads to bones, relatively new protective drugs called bisphosphonates can reduce skeletal damage, says a new systematic review of previous studies. While the new treatment approach does not improve survival rates, it can minimize disabling fractures, spinal cord compression and pain.

19 Jul 2005

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Bortezomib extends lung cancer survival

Thalomid gets FDA approval to treat multiple myeloma

A review of percutaneous kyphoplasty

Four subtypes of blood cancer identified

Breast implants not associated with an increased risk of cancer

Thalidomide improves remission in myeloma

FDA grants priority review for Revlimid

Loyola to study for first time IV medication for osteopenia and inflammatory bowel diseases

Thalomid gives hope for blood cancer sufferers

Compound from Salinispora (marine bacteria) kills blood cancer cells

New treatments suggest that cancer is on the run!

Researchers learn to rapidly rebuild immunity in immune-suppressed cancer patients

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

Scintigraphy scan may help clinicians properly diagnose and then treat two forms of cardiac amyloidosis

Drug AMD-3100 may help cancer patients who need stem cell transplants

Rev/Dex combo looks like a breakthrough treatment for multiple myeloma

Relative of the celebrated COX-2 inhibitor celecoxib is tough tumor fighter

Loyola researchers hope that zoledronic acid will be effective and safe for patients with inflammatory bowel diseases (IBD)

Breast cancer drug Herceptin soon to be widely available on NHS

New protective drugs called bisphosphonates reduce pain and fractures in metastatic breast cancer

How Can CPNs Revolutionize Medical Diagnostics?

World Antimicrobial Awareness Week 2022: What is the burden of antimicrobial resistance?

What Impact is Antimicrobial Resistance having on Animal Health?

Lab Diagnostics & Automation eBook

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

How Can CPNs Revolutionize Medical Diagnostics?

World Antimicrobial Awareness Week 2022: What is the burden of antimicrobial resistance?

What Impact is Antimicrobial Resistance having on Animal Health?

Lab Diagnostics & Automation eBook

Newsletters you may be interested in